A Quicker Oncology Pipeline

Can Brain Cell Death Trigger Multiple Sclerosis?
June 21, 2016
Multiple sclerosis probably looks nothing like you think it does
June 22, 2016
Show all

A Quicker Oncology Pipeline

A new research pathway is bringing novel cancer therapies to patients at a quicker rate.

Oncology treatment is serious business. Lives are at stake, which is why some oncology researchers advocate for a faster path from drug development to approval.

The development of new therapies, for the past several decades, has followed a very clear, step-wise progression. First, there are phase 1 trials to establish a medication’s safety and dose. Next, phase 2 trials explore which cancers are appropriate for the medication. After that, phase 3 trials compare the treatment to existing treatment with the goal of earning FDA approval.

Recently, this timeline seemed to be turned on its ear. Back in 2011, the medication that would later be named Keytruda went through a different process called a first-in-human trial (as opposed to the phase 1, 2, 3 process) since it showed high potential value for cancers that had virtually no other treatment options. This expedited process allowed this beneficial medication to be used by patients (saving some of their lives) years before it could have been used if the standard process was followed.

Keytruda became a model of success. Currently there are at least 40 first-in-human oncology trials underway. This is potentially very good news for cancer patients. But it does need to be noted that not every medication – even if it shows early, positive results – will prove itself to be a therapeutic advance. New doesn’t always mean better. So while any cancer-fighting advances in the oncology pipeline are certainly welcome, health care providers will continue to provide the best options for each patient at the current time. It’s a dual process of hope and pragmatism.

Sources

Prowell TM, Theoret MR, Pazdur R. Seamless oncology-drug development. New Engl J Med 2016;374:2001-3.

Balasubramaniam S, Buzdar A, Flaherty K, et al. The blurring of phase 1, 2, and 3 trials in oncology: Expansion cohorts in phase 1 trials.Conf Clin Cancer Res November 2015.

Read Full Article: A Quicker Oncology Pipeline | BioPlus Specialty Pharmacy

Read Full Article: A Quicker Oncology Pipeline | BioPlus Specialty Pharmacy

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.